The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care.


Journal

European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 22 06 2021
revised: 24 09 2021
accepted: 26 10 2021
pubmed: 6 11 2021
medline: 5 1 2022
entrez: 5 11 2021
Statut: ppublish

Résumé

Hereditary haemorrhagic telangiectasia (HHT) is a complex, multisystemic vascular dysplasia affecting approximately 85,000 European Citizens. In 2016, eight founding centres operating within 6 countries, set up a working group dedicated to HHT within what became the European Reference Network on Rare Multisystemic Vascular Diseases. By launch, combined experience exceeded 10,000 HHT patients, and Chairs representing 7 separate specialties provided a median of 24 years' experience in HHT. Integrated were expert patients who focused discussions on the patient experience. Following a 2016-2017 survey to capture priorities, and underpinned by more than 40 monthly meetings, and new data acquisitions, VASCERN HHT generated position statements that distinguish expert HHT care from non-expert HHT practice. Leadership was by specialists in the relevant sub-discipline(s), and 100% consensus was required amongst all clinicians before statements were published or disseminated. One major set of outputs targeted all healthcare professionals and their HHT patients, and include the new Orphanet definition; Do's and Don'ts for common situations; Outcome Measures suitable for all consultations; COVID-19; and anticoagulation. The second output set span aspects of vascular pathophysiology where greater understanding will assist organ-specific specialist clinicians to provide more informed care to HHT patients. These cover cerebral vascular malformations and screening; mucocutaneous telangiectasia and differential diagnosis; anti-angiogenic therapies; circulatory interplays between anaemia and arteriovenous malformations; and microbiological strategies to counteract loss of normal pulmonary capillary function. Overall, the integrated outputs, and documented current practices, provide frameworks for approaches that augment the health and safety of HHT patients in diverse health-care settings.

Identifiants

pubmed: 34737116
pii: S1769-7212(21)00236-6
doi: 10.1016/j.ejmg.2021.104370
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104370

Informations de copyright

Copyright © 2021. Published by Elsevier Masson SAS.

Auteurs

C L Shovlin (CL)

VASCERN HHT Reference Centre, Imperial College Healthcare National Health Service Trust, London, UK; National Heart and Lung Institute, Imperial College London, UK. Electronic address: c.shovlin@imperial.ac.uk.

E Buscarini (E)

VASCERN HHT Reference Centre, ASST Maggiore Hospital, Crema, Italy. Electronic address: elisabetta.buscarini@asst-crema.it.

C Sabbà (C)

VASCERN HHT Reference Centre, Centro Sovraziendale Malattie Rare, "Frugoni" Internal Medicine Unit, University of Bari "A. Moro", Italy. Electronic address: carlo.sabba@uniba.it.

H J Mager (HJ)

VASCERN HHT Reference Centre, St Antonius Ziekenhuis, Nieuwegein, Netherlands. Electronic address: j.mager@antoniusziekenhuis.nl.

A D Kjeldsen (AD)

VASCERN HHT Reference Centre, Odense University Hospital, Syddansk Universitet, Odense, Denmark. Electronic address: anette.kjeldsen@rsyd.dk.

F Pagella (F)

VASCERN HHT Reference Centre, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. Electronic address: tpagella@libero.it.

U Sure (U)

VASCERN HHT Reference Centre, Essen University Hospital, Essen, Germany; Department of Neurosurgery and Spine Surgery, University Hospital Essen, Germany. Electronic address: Ulrich.Sure@uk-essen.de.

S Ugolini (S)

VASCERN HHT Reference Centre, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. Electronic address: saraugolini5@gmail.com.

P M Torring (PM)

VASCERN HHT Reference Centre, Odense University Hospital, Syddansk Universitet, Odense, Denmark. Electronic address: Pernille.Toerring@rsyd.dk.

P Suppressa (P)

VASCERN HHT Reference Centre, Centro Sovraziendale Malattie Rare, "Frugoni" Internal Medicine Unit, University of Bari "A. Moro", Italy. Electronic address: patrizia.suppressa@gmail.com.

C Rennie (C)

VASCERN HHT Reference Centre, Imperial College Healthcare National Health Service Trust, London, UK. Electronic address: c.rennie08@imperial.ac.uk.

M C Post (MC)

VASCERN HHT Reference Centre, St Antonius Ziekenhuis, Nieuwegein, Netherlands; Department of Cardiology, University Medical Center Utrecht, The Netherlands. Electronic address: m.post@antoniusziekenhuis.nl.

M C Patel (MC)

VASCERN HHT Reference Centre, Imperial College Healthcare National Health Service Trust, London, UK. Electronic address: maneesh.patel@nhs.net.

T H Nielsen (TH)

VASCERN HHT Reference Centre, Odense University Hospital, Syddansk Universitet, Odense, Denmark. Electronic address: troels.nielsen@rsyd.dk.

G Manfredi (G)

VASCERN HHT Reference Centre, ASST Maggiore Hospital, Crema, Italy. Electronic address: guido.manfredi@asst-crema.it.

G M Lenato (GM)

VASCERN HHT Reference Centre, Centro Sovraziendale Malattie Rare, "Frugoni" Internal Medicine Unit, University of Bari "A. Moro", Italy. Electronic address: gmlenato75@libero.it.

D Lefroy (D)

VASCERN HHT Reference Centre, Imperial College Healthcare National Health Service Trust, London, UK. Electronic address: david.lefroy@nhs.net.

U Kariholu (U)

VASCERN HHT Reference Centre, Imperial College Healthcare National Health Service Trust, London, UK. Electronic address: ujwalkariholu@nhs.net.

B Jones (B)

VASCERN HHT Reference Centre, Imperial College Healthcare National Health Service Trust, London, UK. Electronic address: bryony.jones3@nhs.net.

A D Fialla (AD)

VASCERN HHT Reference Centre, Odense University Hospital, Syddansk Universitet, Odense, Denmark. Electronic address: annette.fialla@rsyd.dk.

O F Eker (OF)

VASCERN HHT Reference Centre, Hospices Civils de Lyon, Lyon, France. Electronic address: omer.eker@chu-lyon.fr.

O Dupuis (O)

VASCERN HHT Reference Centre, Hospices Civils de Lyon, Lyon, France. Electronic address: olivier.dupuis@chu-lyon.fr.

F Droege (F)

VASCERN HHT Reference Centre, Essen University Hospital, Essen, Germany; Department of ENT Surgery, University Hospital Essen, Germany. Electronic address: Freya.Droege@uk-essen.de.

N Coote (N)

VASCERN HHT Reference Centre, Imperial College Healthcare National Health Service Trust, London, UK. Electronic address: nicky.coote@nhs.net.

E Boccardi (E)

VASCERN HHT Reference Centre, ASST Maggiore Hospital, Crema, Italy; Niguarda Hospital, Milan, Italy. Electronic address: edoardopietro.boccardi@ospedaleniguarda.it.

A Alsafi (A)

VASCERN HHT Reference Centre, Imperial College Healthcare National Health Service Trust, London, UK. Electronic address: a.alsafi@imperial.ac.uk.

S Alicante (S)

VASCERN HHT Reference Centre, ASST Maggiore Hospital, Crema, Italy. Electronic address: saverio_alicante@hotmail.com.

S Dupuis-Girod (S)

VASCERN HHT Reference Centre, Hospices Civils de Lyon, Lyon, France. Electronic address: sophie.dupuis-girod@chu-lyon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH